Swiss Association for the Study of the Liver (SASL)
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin
Helbling B, Renner E, Meyer-Wyss B, Esteban A, Mullhaupt B, Dinges S, Wilhelmi M, Gonvers J, Borovicka J, Cerny A, Knöpfli M, Stamenic I, Jochum W, Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. Journal of viral hepatitis 2006; 13:762-9.
Nov 1, 2006HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin
Nov 1, 2006Journal of viral hepatitis 2006; 13:762-9
Helbling Beat, Renner Eberhard L, Meyer-Wyss Beat, Esteban Alicia, Mullhaupt Beat, Dinges Sabine, Wilhelmi Martin, Gonvers Jean-Jacques, Borovicka Jan, Cerny Andreas, Knöpfli Marina, Stamenic Ivan, Jochum Wolfram, Swiss Association for the Study of the Liver (SASL)
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
Meyer-Wyss B, Renner E, Arn M, Meyenberger C, Borovicka J, Rossi L, Criblez D, Oneta C, Gonvers J, Rammert C, Mullhaupt B, Helbling B, Egger H, Rich P, Swiss Association for the Study of the Liver (SASL). Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. Journal of viral hepatitis 2006; 13:457-65.
Jul 1, 2006Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
Jul 1, 2006Journal of viral hepatitis 2006; 13:457-65
Meyer-Wyss B, Renner E L, Arn M, Meyenberger Christa, Borovicka Jan, Rossi L, Criblez D, Oneta C, Gonvers J-J, Rammert C, Mullhaupt B, Helbling B, Egger Hp, Rich P, Swiss Association for the Study of the Liver (SASL)